FDA Says Mevacor OTC Label Needs “Major Revisions”
This article was originally published in The Pink Sheet Daily
Agency review finds only 1% of respondents in a label comprehension study correctly said they could use lovastatin 20 mg “right away.” OTC Division’s Ganley cites concerns in a letter to the Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees, which will review J&J/Merck’s Rx-to-OTC switch application.
You may also be interested in...
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
A committee comprising stakeholders will discuss ways of improving USP's work with international pharmacopeias to harmonize excipient monographs and general chapters.